HUM-MOLGEN events: GENOME TRI-CONFERENCE

HUM-MOLGEN -> Events -> Meetings and Conferences

December 06, 2000

Cambridge Healthtech Institute, San Francisco, California
March 3-9, 2001

This year's Genome Tri-Conference will be aimed at exploring new trends and ideas in genomic medicine. As gene databases are mined, numerous targets for diagnostic and therapeutic exploration have amassed. To take advantage of these discoveries and provide answers in the quest for new products, the deployment of sophisticated technologies is required. Learn about these emerging genomic technologies as early stage companies make presentations at the opening meeting, Genomic Partnering. Next, discover the commercial implications of new and established techniques at our core conference, Human Genome Discovery. Finally, learn about recent developments in the field of Gene Functional Analysis during the closing portion of the event. Featured topics at the tri-conference include high throughput methods, chemical genomics, microarray applications, genotyping, and proteomics. Also, using information derived from genomics to design better drugs will be covered. Researchers and executives interested in learning how to implement these strategies in their own organizations should not miss this group of conferences. Find out why CHI's Genome Tri-conference is the must attend event of the year.

Organized by:

Cambridge Healthtech Institute

Invited Speakers:

Dr. Mark D. Adams, Celera Genomics
Dr. Noubar B. Afeyan, NewcoGen Group and AGTC Funds
Dr. Ashok Amin, New York University School of Medicine
Dr. Paul R. Billings, GeneSage, Inc.
Dr. Michael Boyce-Jacino, Orchid BioSciences, Inc.
Dr. Andreas Braun, Sequenom, Inc.
Dr. Mark Chee, Illumina, Inc.
Mr. Scott Clarke, BioSpace.com
Dr. Mark I. Cockett, Bristol-Myers Squibb Pharmaceutical Research Institute
Dr. Robert Cook-Deegan, Georgetown University and Stanford-in-Washington Program
Dr. Kenneth W. Culver, Novartis Pharmaceuticals Corporation
Dr. Vishva M. Dixit, Genentech, Inc.
Dr. Björn Ekström, Pyrosequencing AB
Dr. Stephen P.A. Fodor, Affymetrix, Inc.
Dr. Lance Fors, Third Wave Technologies, Inc.
Dr. Stephen H. Friend, Rosetta Inpharmatics, Inc.
Dr. David Galas, Keck Graduate Institute of Applied Life Sciences
Dr. Tim Harris, Structural GenomiX, Inc.
Dr. Elaine Heron, PE Applied Biosystems
Dr. Arthur L. Holden, The SNP Consortium
Mr. Steven H. Holtzman, Millennium Pharmaceuticals, Inc.
Dr. Jon Faiz Kayyem, Clinical Micro Sensors/Motorola
Dr. Klaus Lindpaintner, F. Hoffmann-La Roche AG
Dr. Rich B. Meyer, Protogene Laboratories, Inc.
Prof. Robert P. Merges, University of California, Berkeley School of Law
Dr. Michio Oishi, Kazusa DNA Research Institute
Dr. David J. O'Reilly, Iconix Pharmaceuticals, Inc.
Dr. Ari Patrinos, U.S. Department of Energy
Dr. Patrick Plewman, diaDexus
Dr. Allen D. Roses, GlaxoWellcome Research and Development
Dr. Jonathan M. Rothberg, CuraGen Corporation
Dr. Steve Ruben, Human Genome Sciences
Dr. Brent A. Rupnow, Hoffmann-La Roche Inc.
Dr. Randy Scott, Incyte Genomics Inc. and Genomic Health, Inc.
Prof. John Todd, University of Cambridge
Dr. Jackson Wan, R. W. Johnson Pharmaceutical Research Institute
Dr. Gregory Went, DNA Sciences
Dr. David G. Wang, First Genetic Trust

Deadline for Abstracts:

February 2, 2001

Registration:

Available on-line

E-mail:

jlaakso@healthtech.com

Posted by:

Jennifer Laakso

Host:

wks217.healthtech.com